InVivoScribe

Founded in 1999 and headquartered in San Diego, CA, InVivoScribe has established itself as a pioneer in precision diagnostics for hematologic malignancies. The company operates a dual business model, offering both a portfolio of regulated diagnostic products (CE-IVD, IVD) and a global network of CLIA-certified clinical laboratories (LabPMM). Its core strength lies in its proprietary assays for biomarkers like FLT3 and NPM1, its role as a streamlined CDx development partner for pharma, and its leadership in MRD testing, positioning it at the intersection of diagnostics, personalized medicine, and drug development support.

Integrated molecular diagnostics platform utilizing Sanger sequencing, fragment analysis (capillary electrophoresis), next-generation sequencing (NGS), and digital PCR (dPCR). Includes proprietary assays (e.g., LeukoStrat®, LymphoTrack®), specialized analysis software, and manufactured reagents/controls for standardized detection of genetic biomarkers, clonality, and minimal residual disease (MRD) in blood cancers.

InVivoScribe competes with large, diversified diagnostics companies (e.g., Roche, Abbott, Quest, Labcorp) in the oncology testing space and with specialized molecular diagnostic firms (e.g., Adaptive Biotechnologies in immune sequencing). Its differentiation lies in its deep, exclusive focus on hematologic cancers, its integrated product-and-service model, and its proven track record as a global CDx co-development partner.